Shares of Janux Therapeutics, Inc. (JANX) surged 5.08% intraday on Tuesday, outperforming the broader markets.
The rally in JANX stock was likely driven by an analyst report from BTIG maintaining a Buy rating on the company. Positive analyst coverage often boosts investor confidence and demand for a stock.
In the report, analyst Justin Zelin reiterated his bullish stance on Janux Therapeutics, though the price target was not disclosed. The firm's continued optimism on the company's prospects provided a sentiment boost for JANX shares.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。